Assertio Announces Results Of A Clinical Trial Investigating The Utility Of Rolvedon Injection When Dosed The Same Day Of Chemotherapy For Patients With Early Stage Breast Cancer
Assertio Announces Results Of A Clinical Trial Investigating The Utility Of Rolvedon Injection When Dosed The Same Day Of Chemotherapy For Patients With Early Stage Breast Cancer
Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (ESBC). The results were presented as part of the San Antonio Breast Cancer Symposium by the American Association of Cancer Research and the University of Texas Health Science Center at San Antonio.
具有全面商业能力为患者提供差异化产品的制药公司Assertio Holdings, Inc.（“Assertio” 或 “公司”）（纳斯达克股票代码：ASRT）昨天公布了一项临床试验结果，该试验调查了Rolvedon（eflapegrastim-xnst）注射剂在当天对早期乳腺癌（ESBC）患者进行化疗时的效用。研究结果由美国癌症研究协会和德克萨斯大学圣安东尼奥健康科学中心作为圣安东尼奥乳腺癌研讨会的一部分公布。
In this open-label, single-arm study (NCT04187898), conducted across 13 sites in the US, individuals received Rolvedon 30 minutes post chemotherapy for ESBC. Rolvedon demonstrated 1.8 days to neutrophil count recovery and a febrile neutropenia rate of 2%. Zero patients required the need for hospitalization and/or intervention for febrile neutropenia. No new safety signals were identified.
在这项在美国13个地点进行的开放标签单臂研究（NCT04187898）中，个人在ESBC化疗30分钟后接受了Rolvedon治疗。罗尔维登显示中性粒细胞计数恢复1.8天，发热性中性粒细胞减少率为2％。发热性中性粒细胞减少需要住院和/或干预的患者为零。没有发现新的安全信号。
